FDA clears Novartis’ oral drug for chronic hives
Novartis has claimed a first-in-class regulatory approval in the US for oral BTK inhibitor remibrutinib as a second-line…
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable…
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be…
Novartis Weighs US Buildout And Rhapsido Launch In Growth Outlook
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly…
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase…